ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0021

Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA

Hideto Takada1, Yuko Okamoto2, Yasuhiro Katsumata3, Jennifer Seifert4, Kristen Demoruelle5, Jill Norris6, Kevin Deane7, Masayoshi Harigai3 and V. Michael Holers8, 1Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Japan, 2Tokyo Women's Medical University Division of Rheumatology, 10-22 Kawada-cho, Shinjyuku-ku, Tokyo, Japan, 3Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 4University of Colorado School of Medicine, Littleton, CO, 5University of Colorado Anschutz Medical Campus, Aurora, CO, 6Colorado School of Public Health, Aurora, CO, 7University of Colorado Denver, Denver, CO, 8University of Colorado, Denver, CO

Meeting: ACR Convergence 2021

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Etiology & Pathogenesis Poster (0011–0045)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Production of autoantibodies following pathogenic T and B cell interactions precede the development of RA. T follicular helper (Tfh) cells and T peripheral helper (Tph) cells are capable of providing B-cell help and both are increased in the peripheral blood in patients with seropositive RA. However, it is unknown whether these cell populations are expanded and/or altered in the peripheral blood prior to the onset of clinically apparent RA. Moreover, the contribution of these cells to the pathogenesis of RA may differ according to genetic and environmental backgrounds. Herein, we explored circulating Tph (cTph) cells and circulating Tfh (cTfh) cells from anti-citrullinated protein antibodies (ACPA)+ individuals both before and after development of RA in two ethnically distinct populations.

Methods: We recruited 14 and 10 ACPA+ individuals without arthritis but at-risk of future RA (ARI), 15 and 10 ACPA+ patients with early RA (2010 criteria and < 1 year from diagnosis), and 14 and 15 healthy controls (HC) from the Studies of the Etiologies of RA (SERA) population at University of Colorado (CU) and the rheumatology outpatient clinic at Tokyo Women’s Medical University (TWMU) in Japan, respectively (Table 1). Cryopreserved peripheral blood mononuclear cells were analyzed by flow cytometry to quantify cTph cells (PD-1hiCXCR5−CD4+ memory T cells) and cTfh cells (PD-1hiCXCR5+CD4+ memory T cells). We also assessed the expression of activation markers, HLA-DR and ICOS, on these cells.

Results: In both ethnic populations, cTph cells were significantly increased in RA but not in ARI compared to HC (Figure 1A and 2A). In the CU population, the frequency of cTph cells was moderately correlated with serum IgM-RF levels in both ARI (Spearman’s ρ=0.56, p=0.04) and RA (Spearman’s ρ=0.68, p=0.005) (Figure 1B), while no correlation was observed between the frequencies of cTph cells and serum ACPA levels in either ARI or RA. There were no significant differences in the expressions of HLA-DR and ICOS on cTph cells or cTfh cells between CU study groups (Figure 1C). Unlike the CU population, the TWMU population did not show positive correlation between the frequency of cTph cells and serum IgM-RF levels in either ARI or RA (Figure 2B). In that population, however, the expression of HLA-DR on cTph cells was increased in both ARI and RA (Figure 2C).

Conclusion: cTph cells were expanded in RA but not in ARI in both ethnic populations, suggesting a relationship of these cells with clinically-apparent inflammatory arthritis. In addition, unique alterations in cTph cells among ACPA+ individuals with different ethnic backgrounds and in relationship to IgM-RF suggest their shared importance but potentially different roles in the future transition of ACPA+ ARI to early RA.

Table 1. Demographic characteristics of the study subjects.

Figure 1. Flow cytometry analysis of cTph and cTfh cells in ACPA+ individuals at-risk of future RA (ARI) and ACPA+ early RA patients, and healthy controls (HC) at University of Colorado. A) Frequencies of cTph and cTfh cells in each study group. B) Correlation between frequencies of cTph or cTfh cells and serum IgM-RF levels in ARI and RA. C) Expression of HLA-DR on cTph or cTfh cells in each study group. P-values were calculated using Kruskal-Wallis one-way analysis of variance followed by Dunn’s multiple comparisons test (Panel A and C) and Spearman’s rank correlation (Panel B).

Figure 2. Flow cytometry analysis of cTph and cTfh cells in ACPA+ individuals at-risk of future RA (ARI) and ACPA+ early RA patients, and healthy controls (HC) at Tokyo Women’s Medical University. A) Frequencies of cTph and cTfh cells in each study group. B) Correlation between frequencies of cTph or cTfh cells and serum IgM-RF levels in RA and ARI. C) Expression of HLA-DR on cTph or cTfh cells in each study group. P-values were calculated using Kruskal-Wallis one-way analysis of variance followed by Dunn’s multiple comparisons test (Panel A and C) and Spearman’s rank correlation (Panel B).


Disclosures: H. Takada, None; Y. Okamoto, None; Y. Katsumata, Glaxo-Smithkline K.K., 6, Sanofi K.K., 6, AstraZeneca K.K., 6, Chugai Pharmaceutical Co., Ltd., 6, Pfizer Japan Inc., 6, Astellas Pharma Inc., 6, Mitsubishi Tanabe Pharma Corporation, 6, Janssen Pharmaceutical K.K., 6; J. Seifert, None; K. Demoruelle, Pfizer, 5; J. Norris, None; K. Deane, Inova Diagnostics, Inc, 5, Bristol Meyers Squibb, 1, 5, Janssen Research and Development, LLC, 5, imaware, 2, ThermoFisher, 2, 5, Medscape, 6; M. Harigai, None; V. Holers, Jansson, 5.

To cite this abstract in AMA style:

Takada H, Okamoto Y, Katsumata Y, Seifert J, Demoruelle K, Norris J, Deane K, Harigai M, Holers V. Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/unique-alterations-in-circulating-t-peripheral-helper-cells-are-found-in-different-ethnic-groups-of-acpa-individuals-both-at-risk-for-and-with-classified-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unique-alterations-in-circulating-t-peripheral-helper-cells-are-found-in-different-ethnic-groups-of-acpa-individuals-both-at-risk-for-and-with-classified-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology